A recent Infectious Disease digest,
as sent to subscribers

Study Type: Multisociety consensus position paper (expert panel guidance, not primary research)

Key Question: What hospital-level, infection-focused strategies can complement existing sepsis guidelines and quality measures to improve sepsis care and outcomes?

Key Findings:

• Recommendations span six domains: diagnostics/pathogen detection, antimicrobial management, surveillance/metrics, adjunctive therapy, programme infrastructure, and infection prevention.
• Specific actionable measures include rapid multiplex blood culture PCR with stewardship support, prioritising β-lactam before vancomycin via clinical decision support, prolonged-infusion antipseudomonal β-lactams in critical illness, EHR-based sepsis surveillance, tracking de-escalation/source control timeliness, corticosteroids for severe CAP, and routine tooth brushing to reduce hospital-acquired pneumonia.
• Emerging diagnostic strategies are flagged as promising but not yet ready for routine adoption pending further validation.

Clinical Relevance: Offers UK ID clinicians and antimicrobial stewardship teams a practical, evidence-informed framework to strengthen infection-related sepsis pathways beyond existing bundles (e.g., NHS Sepsis Six), particularly around diagnostics, antibiotic optimisation, and infection prevention.

Limitations: As a US-focused consensus document based on expert opinion rather than new trial data, recommendations may require adaptation for NHS infrastructure, resourcing, and existing quality frameworks.

Study Type: Retrospective cohort study

Key Question: Does atypical presentation of CDI (dominant dysmotility/ileus features preceding diarrhoea) affect diagnostic timeliness and mortality compared with typical diarrhoeal-onset CDI?

Key Findings:

• Among 467 CDI episodes, 32% had dysmotility at diagnosis (radiologically persisting up to 6 weeks); small-bowel involvement seen in 16.3% of baseline imaging.
• Atypical presentations (19.5% of episodes) had delayed treatment initiation (median 4 vs 2 days, P<.001) and higher 90-day mortality (24.2% vs 9.6%; HR 2.62, 95% CI 1.51–4.57, P=.001).

Clinical Relevance: UK clinicians should maintain a high index of suspicion for CDI in patients with unexplained ileus or gastrointestinal dysmotility even before diarrhoea develops, as delayed recognition is linked to significantly worse outcomes, supporting review of current UK/NICE CDI diagnostic pathways.

Limitations: Single-centre retrospective design limits generalisability and causal inference regarding the dysmotility–mortality relationship.

Study Type: Case report with ethical analysis (commentary)

Key Question: How should clinicians navigate antiretroviral treatment decisions (oral vs long-acting injectable) when they intersect with immigration status and administrative/legal considerations?

Key Findings:

• A case of a woman with HIV and irregular migration status requesting a switch to long-acting injectable therapy, motivated partly by anticipated immigration-related benefits and discretion rather than purely clinical need.
• Applying Beauchamp and Childress's principlism alongside Tronto's ethics of care reveals tensions between autonomy, justice, beneficence, and non-maleficence when treatment choice may be perceived as influencing residency outcomes.
• Treatment interruption risk is heightened by legal instability, complicating standard clinical reasoning around regimen switching.

Clinical Relevance: UK clinicians managing migrant patients with insecure immigration status (relevant given NHS charging regulations and Home Office interactions) may face analogous dilemmas where therapeutic decisions become entangled with legal/administrative consequences, highlighting a need for professional guidance.

Limitations: As a single case-based ethical commentary, findings are illustrative rather than generalisable and offer no empirical outcome data.

Study Type: Post-hoc reanalysis of a randomized controlled trial

Key Question: Does applying a Desirability of Outcome Ranking (DOOR) framework, integrating mortality, treatment failure, and severe adverse events, change the assessment of voriconazole versus amphotericin B deoxycholate for invasive aspergillosis compared to mortality-based endpoints alone?

Key Findings:

• Voriconazole demonstrated superior overall outcomes compared to amphotericin B deoxycholate when assessed using the composite DOOR endpoint.
• The abstract does not report specific probability-of-better-outcome statistics, effect sizes, or confidence intervals.

Clinical Relevance: Supports voriconazole's established first-line status for invasive aspergillosis in NHS antifungal guidelines by demonstrating benefit across a broader, patient-centred outcome measure rather than mortality alone.

Limitations: This is a secondary reanalysis of an older trial using amphotericin B deoxycholate, a comparator no longer standard practice, limiting direct applicability to current treatment choices (e.g., liposomal formulations).

Study Type: Retrospective cohort study

Key Question: Can peak absolute eosinophil count (AEC) or serum IgE reliably distinguish parasitic from non-parasitic causes of marked eosinophilia?

Key Findings:

• Among 1,025 patients (360 with parasitic infection), median peak AEC was significantly lower in parasitic vs non-parasitic diagnoses.
• ROC-derived cutoffs of AEC >28,680/µL (adults) and >59,529/µL (children) excluded parasitic infection with near-100% specificity; only 2 parasitic cases (paediatric VLM) exceeded 30,000/µL.
• Rising AEC in adults correlated with increasing likelihood of malignancy-associated eosinophilia (χ²trend=84.69, p<0.0001); serum IgE showed no diagnostic discriminatory value.

Clinical Relevance: Provides UK ID/haematology clinicians a practical AEC threshold (>30,000/µL) to deprioritise parasitic work-up and expedite investigation for malignancy or hypereosinophilic syndrome, potentially streamlining NHS eosinophilia pathways.

Limitations: Single-centre (NIH) retrospective cohort with likely referral bias toward complex/refractory cases, limiting generalisability to routine UK populations.

Study Type: Systematic review and meta-analysis (of registrational RCTs)

Key Question: Does pooling acute pyelonephritis (AP) with other complicated UTIs (cUTIs) in registrational antibiotic trials mask meaningful differences in treatment outcomes?

Key Findings:

• Across 10 RCTs (n=5,971), AP was associated with significantly higher composite cure at test-of-cure than other cUTIs (RR 1.12; 95% CI 1.03–1.23; I²=82%; prediction interval crossing 1).
• Composite endpoint differences were driven mainly by microbiologic eradication (r=0.98) rather than clinical cure (r=0.30).
• In the one trial with subtype-stratified data (ADAPT-PO), the AP advantage was far larger for microbiologic eradication (+15.6pp) than clinical response (+3.5pp); generalisability to other trials could not be confirmed.

Clinical Relevance: UK clinicians interpreting cUTI trial data (informing antibiotic licensing and local formulary decisions) should recognise that pooled AP/cUTI outcomes may overstate efficacy for non-pyelonephritis cUTIs, affecting extrapolation to real-world prescribing.

Limitations: Substantial heterogeneity in AP/cUTI definitions and near-universal absence of outcome-component stratification limit confidence in generalising the single stratified trial's findings across the pooled dataset.

Study Type: Retrospective cohort study

Key Question: Does including valve leaflet thickening as a major imaging criterion improve or compromise diagnostic accuracy of the 2023 Duke-ESC criteria for infective endocarditis (IE)?

Key Findings:

• Among 3,747 episodes investigated for suspected IE, leaflet thickening was found in 288 (8%); IE was ultimately diagnosed in 67% of these.
• Adding leaflet thickening increased sensitivity of the 2023 Duke-ESC criteria from 59% (95% CI 52–66%) to 79% (95% CI 73–85%), but specificity fell sharply from 98% (95% CI 93–100%) to 46% (95% CI 36–57%).
• 32% of confirmed IE episodes with leaflet thickening had no other typical intracardiac lesion, and half of IE cases still met major imaging criteria even without leaflet thickening.

Clinical Relevance: UK ID clinicians applying the 2023 Duke-ESC criteria should be cautious using leaflet thickening as a major imaging criterion, as it markedly increases false-positive IE diagnoses and risks unnecessary antibiotic courses or valve surgery.

Limitations: Single-centre retrospective design limits generalisability and may introduce selection or diagnostic bias.

Study Type: Case series

Key Question: Is autochthonous canine pythiosis, a rare oomycete infection, emerging in Italy, and what is its environmental and molecular epidemiology?

Key Findings:

• 7 autochthonous canine pythiosis cases identified in Italy (2021–2024), all with documented freshwater exposure across multiple lakes.
• Cases recurred over consecutive years, suggesting an established environmental reservoir rather than isolated events.
• Molecular sequencing placed isolates within clade IV of the *Pythium insidiosum* species complex, now designated *Pythium periculosum*.

Clinical Relevance: UK clinicians should be aware of pythiosis as an emerging, difficult-to-diagnose oomycete infection with expanding European geographic range, relevant to travel/import history in dogs and as a rare zoonotic differential in humans with similar freshwater exposure.

Limitations: Small case numbers limit generalisability and preclude firm conclusions on incidence trends or environmental risk factors.